REG - Genflow Biosciences - Update on Animal Health Program

Genflow BiosciencesAnnouncement

10/10/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251010:nRSJ8229Ca&default-theme=true

RNS Number : 8229C  Genflow Biosciences PLC  10 October 2025

 

 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO
CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION
(EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN
UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS
CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

10 October 2025

 

Genflow Biosciences Plc

 

Update on Animal Health Program

 

LONDON, UK-Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the
Company"), the only publicly listed longevity company in Europe, is pleased to
provide an update on its Dog Aging (GF-1004) study, a proof-of-concept
clinical trial evaluating the safety and efficacy of its proprietary
SIRT6-centenarian gene therapy for age-related decline in elderly dogs.

 

Genflow's proprietary centenarian SIRT6 gene therapy has now been administered
for the second time in its ongoing randomized, controlled trial involving 28
beagles aged 10 years and older. In March, recipients received three different
modalities of SIRT6 gene therapy with no ill or adverse effects observed,
while control animals remained untreated. The repeat administration has again
demonstrated an excellent safety and tolerability profile, marking a key
milestone in the study. The dogs are in a follow-up period expected to
conclude in January 2026.

 

This successful second administration underscores the robustness of Genflow's
gene therapy platform and its potential applicability beyond human health. The
SIRT6 gene, sourced from human centenarians, plays a vital role in DNA repair,
metabolic regulation, and resistance to age-related decline. By leveraging
this unique gene variant, Genflow aims to introduce a new class of
longevity-based treatments into the multi-billion-dollar global animal health
market, targeting improved healthspan, vitality, and lifespan in companion and
livestock animals.

 

Dr. Eric Leire, Chief Executive Officer of Genflow Biosciences, commented:
"We're very encouraged by the continued safety validation of our SIRT6 therapy
and by the strong engagement we're seeing from established players in the
animal health industry. The animal health market represents an attractive
near-term commercial opportunity for Genflow, complementing our core human
longevity programs while showcasing the broader potential of our gene therapy
platform."

 

With safety confirmed in repeat administration, Genflow will continue to
advance its animal health initiative toward the next stage of clinical
evaluation and partnership development. The Company remains committed to
creating value for shareholders through innovation, collaboration, and
leadership in the emerging field of genetic longevity therapeutics.

 

Contacts

 Genflow Biosciences  Harbor Access
 Dr Eric Leire, CEO   Jonathan Paterson, Investor Relations
 +32-477-495-881      +1 475 477 9401
                      Jonathan.Paterson@Harbor-access.com

 

 Corporate Brokers
 Capital Plus Partners Ltd
 Jon Critchley, +44 207 432 0501

 

About Genflow Biosciences

 

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising results.
Genflow's 12-month proof-of-concept clinical trial evaluating their
SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other
programs planned include a clinical trial that will explore the potential
benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated
Steatohepatitis), the most prevalent chronic liver disease for which there is
no effective treatments. Please visit www.genflowbio.com
(http://www.genflowbio.com/)   and follow the Company on LinkedIn
(https://www.linkedin.com/company/genflow-biosciences/?viewAsMember=true)
 and X (https://x.com/genflowbio) .

 

DISCLAIMER

The contents of this announcement have been prepared by, and are the sole
responsibility of, the Company.

This announcement may contain forward-looking statements. The forward-looking
statements include, but are not limited to, statements regarding the Company's
or the Directors' expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statement that refers to projections,
forecasts or other characterisations of future events or circumstances,
including any underlying assumptions, is a forward-looking statement. The
words "anticipate", "believe", "continue", "could", "estimate", "expect",
"intend", "may", "might", "plan", "possible", "potential", "predict",
"project", "seek", "should", "would" and similar expressions, or in each case
their negatives, may identify forward-looking statements, but the absence of
these words does not mean that a statement is not forward-looking.

Forward-looking statements include all matters that are not historical facts.
Forward-looking statements are based on the current expectations and
assumptions regarding the Company, the business, the economy and other future
conditions. Because forward-looking statements relate to the future, by their
nature, they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict. Forward-looking statements are
not guarantees of future performance and the Company's actual financial
condition, actual results of operations and financial performance, and the
development of the industries in which it operates or will operate, may differ
materially from those made in or suggested by the forward-looking statements
contained in this announcement. In addition, even if the Company's financial
condition, results of operations and the development of the industries in
which it operates or will operate, are consistent with the forward-looking
statements contained in this announcement, those results or developments may
not be indicative of financial condition, results of operations or
developments in subsequent periods. Important factors that could cause actual
results to differ materially from those in the forward-looking statements
include regional, national or global, political, economic, social, business,
technological, competitive, market and regulatory conditions.

Any forward-looking statement contained in this announcement applies only as
of the date of this announcement and is expressly qualified in its entirety by
these cautionary statements. Factors or events that could cause the Company's
actual plans or results to differ may emerge from time to time, and it is not
possible for the Company to predict all of them. The Company expressly
disclaims any obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained in this announcement to
reflect any change in its expectations or any change in events, conditions or
circumstances on which any forward-looking statement contained in this
announcement is based, unless required to do so by applicable law, the
Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and
Transparency Rules of the FCA or the UK Market Abuse Regulation.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUKVBRVVURRAA